Magid Abou-Gharbia, Ph.D., FRSC is currently Laura H. Carnell Professor of Medicinal Chemistry and Director of the Moulder Center for Drug Discovery Research (MCDDR) at the School of Pharmacy, Temple University, Philadelphia, PA. He is responsible for Setting and implementing School of Pharmacy research strategies to bridging preclinical research with clinical research “from Bench to Patient-Bedside” and promoting the school’s research and entrepreneurial enterprise. Prior to joining Temple University in 2008, Magid spent 26 years at Wyeth Pharmaceuticals where he was Senior Vice President Discovery Research.
As Senior Vice President & Head of Chemical & Screening Sciences at Wyeth, he was responsible for overseeing and directing Wyeth chemistry and screening research efforts of 500 scientists at 4 US research facilities and 150 chemists in Hyderabad, India in support of drug discovery in Neuroscience, Inflammation, Women's Health/Bone, Oncology and Cardiovascular/Metabolic Diseases therapeutic areas. AbouGharbia led research efforts that resulted in the Discovery of 10-marketed drugs across multiple therapeutic areas. Four Drugs for treatment of Cancer and increasing the life expectancy of patients in need (Mylotarg, Torisel, Bosulif and Neratinib), other drugs for treatment of osteoporosis (Combrinza), 2 antidepressants (Effexor, Pristique), for insomnia (Sonata), for neuropathic pain (Dezocine) and for bacterial resistant infections (Tygacil).
Dr. Abou-Gharbia has also been instrumental in establishing and promoting biomedical research in the Middle East. Among his recent contributions are the establishment of Qatar Biomedical Research Institute (QBRRI) and promoting medicinal chemistry and drug discovery research at major educational institutions in the region. Establishing collaborations with several academic and research institutions in the region, among which: The University of Sharjah’s School of Pharmacy in the UAE, Misr University for Science and Technology (MUST) in Egypt, Future University in Egypt (FUE), City of Scientific Research and Technological Applications (SERTA-City) in Egypt, British University in Egypt (BUE) and Cairo University. In addition, he continue to welcome and host visiting scholars, faculty and students in his laboratories in an effort to further boost biomedical research in the region through training them in modern drug discovery approaches. His efforts working with ACS to enhance Chemistry image and facilitate collaboration and global networking between chemists, led to the launch of several key ACS initiatives such as, initiating ACS Heroes of Chemistry Award in 1996, Pharma Leadership meeting in 2003 and holding first joint symposium between ACS MedChem and European federation of Medicinal Chemistry (EFMC) in 2006.
His research contributions in the past 10 years at Temple University resulted in establishing Moulder Center for Drug Discovery Research (https://moulder.temple.edu/ ), a State-of-the-Art academic Drug discovery Center. Moulder Center’s accomplishments included receiving several research grants, the publications of numerous research papers in peer-reviewed journals, the filing of over 35 US patents and the formation of 3 spin off companies and 2 additional spin off companies are in progress and licensing of his school’s IP to external companies.
He serves on the Scientific Advisory Board of several companies and professional societies and has adjunct professor appointments at several universities in the US and abroad. His research achievements resulted in more than 125 US patents, over 350 worldwide Patents, 325 publications, invited lectures and presentations. In 1998, the US Patent & Trademark Office named him as one of the most Prolific Inventors of the Decade during 1987-1997.
Dr. Abou-Gharbia received numerous awards and honors, among which 2 ACS Heroes of Chemistry awards in 2008 for the discovery of Torisel, first m-TOR inhibitor anticancer drug and 2014 for discovery of Effexor, first SNRI antidepressant drug. In 2014 he was named "Researcher and Educator of the Year" by the Philadelphia Business Journal and the PA Bio Organization and he received The Grand Hamdan International Award in the Field of Medical Sciences and Drug Discovery.